Farmakokinetika ceftriaksona u teladi by Jayesh J. Maradiya et al.
1ISSN 0372-5480Printed in Croatia
VETERINARSKI ARHIV 80 (1), 1-9, 2010
 Pharmacokinetics of ceftriaxone in calves
Jayesh J. Maradiya, Harshad V. Goriya, Shailesh K. Bhavsar*, 
Urvesh D. Patel, and Aswin M. Thaker
Department of Pharmacology and Toxicology, College of Veterinary Science and Animal Husbandry, Anand 
Agricultural University, Anand, India
MARADIYA, J. J., H. V. GORIYA, S. K. BHAVSAR, U. D. PATEL, A. M. THAKER: 
Pharmacokinetics of ceftriaxone in calves. Vet. arhiv 80, 1-9, 2010.
ABSTRACT
The pharmacokinetics of ceftriaxone was determined after a single intravenous and intramuscular admini-
stration at the dose rate of 10 mg/kg in crossbred cow calves. The drug concentration in plasma was quantifi ed 
through High Performance Liquid Chromatography with UV detection. Following intravenous administration 
the drug was rapidly distributed (t
1/2α: 0.13 ± 0.01 h; Vd(area); 0.44 ± 0.07 L/kg) and eliminated (t1/2β: 1.58 ± 0.06 
h) from the body with a clearance rate of 3.15 ± 0.41 mL/min/kg. Following intramuscular administration, 
the peak plasma drug concentration (C
max
) was 15.34 ± 2.39 μg/mL at 0.25 hours (T
max
) suggesting very rapid 
absorption. The drug was extensively distributed (Vd
(area)
: 1.16 ± 0.15 L/kg) and slowly eliminated (t
1/2β: 5.02 ± 
0.51 hours; Cl
(B)
: 2.71 ± 0.29 mL/min/kg) following intramuscular administration. The absolute bioavailability 
of ceftriaxone was 47.0 ± 5.0% following intramuscular injection. However, it can be used at a dosage of 10 
mg/kg intramuscularly, repeated at twelve-hourly intervals, for the treatment of susceptible bacteria infections 
in calves.
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Introduction
Ceftriaxone is a third-generation semi-synthetic bactericidal cephalosporin antibiotic, 
resistant to various types of bacterial β-lactamases. It has excellent activity against gram-
negative bacteria as well as a wide range of gram-positive and some anaerobic bacteria, 
including enterobacteriaceae, Streptococcus pneumoniae, Haemophilus infl uenzae, 
Pseudomonas aeruginosa and other non-enterococcal streptococci (NEU et al., 1981; 
RICHARDS et al, 1984; BROGDEN and WARD, 1988). It has rapid absorption and wide 
distribution in tissues as well as body fl uids, after parenteral administration in animals 
(CHRIST, 1991). The drug thus seems to be useful in the treatment of a variety of bacterial 
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infections, including meningitis, septicemia, pyoderma, colibacillosis, surgical prophylaxis 
and urinary tract, respiratory tract, wound, soft tissue and joint infections (RICHARDS et 
al., 1984). Pharmacokinetic studies of a drug are essential for its judicious use in animals. 
Despite the great potential for clinical use of the drug in veterinary medicine, the data on its 
pharmacokinetics following intravenous and intramuscular administration in cow calves 
are limited (SOBACK and ZIV, 1988; JOHAL and SRIVASTAVA, 1998, 1999). Therefore, the 
objective of the present study was to determine the pharmacokinetics and bioavailability 
of ceftriaxone following a single intravenous and intramuscular administration at a dose 
rate of 10 mg/kg body mass in crossbred calves. 
Materials and methods
Experimental animals. The experiment was done on six healthy, male, domestic 
crossbred (Kankrej × Jersey) calves weighing 55-105 kg (aged 6-9 months). The calves 
were kept under constant observation for two weeks before commencing the experiment, 
without any antibiotic treatment. They were subjected to clinical examination during this 
period, in order to exclude the possibility of any disease. They were housed in sheds with 
concrete fl oors and were maintained on concentrate, green fodder and dry grass. Water 
was provided ad libitum. 
Chemicals. Ceftriaxone sodium (Vetaceph Injection containing sterile ceftriaxone 
sodium USP equivalent to 1 g ceftriaxone) was obtained from Unichem Laboratories Ltd., 
Mumbai, India. Acetonitrile and Methanol (HPLC grade), N-acetyl -N, N, N-trimethyl 
ammonium bromide, Orthophosphoric acid (88%) were procured from Loba chemical 
Ltd, Mumbai, India and Ranbaxy Fine Chemicals Ltd., New Delhi, India.
Drug administration and sample collection. The calves were randomly allocated to 
receive either an intravenous or intramuscular injection of ceftriaxone sodium at the dose 
rate of 10 mg/kg. A washout period of 2 weeks was observed between treatments. The 
intravenous injection was administered in the jugular vein. Blood samples (5 mL each) 
were collected through an intravenous catheter fi xed in the contra-lateral jugular vein, in 
heparinized glass test tubes, before administration and at 2, 5, 10, 15, 30 minutes and 1, 
1.5, 2, 4, 6, 8, 12, 24, and 36 hours after intravenous administration. The intramuscular 
injection was administered in the gluteal muscles. Blood samples were collected before 
administration and at 2, 5, 10, 15, 30 minutes and 1, 2, 4, 6, 8, 12, 24 and 36 hours after 
the intramuscular administration of the drug. Plasma was separated by centrifugation at 
3000 g for 10 minutes at room temperature, stored at -20 °C and analyzed within 24 h. 
Analytical assay of ceftriaxone and pharmacokinetic analysis. Plasma ceftriaxone 
concentration was determined by the High Performance Liquid Chromatography (HPLC) 
assay, with minor modifi cations (HAKIM et al., 1988). The HPLC system (Merck-
Hitachi LaChrom) consists of an isocratic pump (L-7110) with an online degasser (L-
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7612), interface (D-7000), UV detector (7400), autosampler (7200), sample cooler 
(L-7200), chromatography data station software (D-7000) and multi HSM-manager. 
Chromatographic separation was done using Lichrocart RP-18 column (250 mm × 4 mm) 
at room temperature.
Samples (250 μL) were deproteinized by the addition of acetonitrile (500 μL), and 
vortexed for one minute, followed by centrifugation at 3000 g for 10 minutes. A clear 
supernant fl uid was decanted into a glass insert (automatic sampler vessels) from which 
50 μL was injected into the HPLC system. The mobile phase consisted of a mixture of 
buffer and acetonitrile (62:38). The buffer was prepared by dissolving 1.78 g di-sodium 
hydrogen phosphate dihydrate and 1.0 g N-acetyl -N, N, N-trimethyl ammonium bromide 
in 950 mL HPLC water, pH (7.0) was adjusted with orthophosphoric acid. The mobile 
phase was fi ltered through a 0.45 μm Millipore fi lter. The mobile phase was pumped 
through a column at a fl ow rate of 1.0 mL/min, at an ambient temperature of 25 °C. 
The elute was monitored at a wavelength of 254 nm. All chemicals used in the present 
study were of HPLC grade. Ceftriaxone standards (0.19, 0.26, 0.52, 1.68, 4.93, 14.94, 
49.79, 76.59, 90.11, 100.12 μg/mL) were prepared by serial dilutions of stock solution 
(100.12 μg/mL) in the drug-free plasma of calves. A calibration curve was prepared 
for drug concentrations ranging from 0.19 to 100.12 μg/mL and was used to quantify 
the drug concentration in samples. The calibration curve was prepared daily. The assay 
was sensitive and reproducible, and linearity was observed from 0.19 to 100.12 μg/mL 
(R2≥0.99). The lower limit of quantifi cation of assay was 0.19 μg/mL. Precision and 
accuracy were determined using quality control (QC) samples at concentrations of 
1.68, 14.94, and 100.12 μg/mL (5 replicates each, per day). The intraday and interday 
coeffi cients of variation (COV%) for 5 QC samples were satisfactory, with relative 
standard deviations (RSD) of less than 7.5%. Intraday and interday variations were 
within acceptable limits. Different pharmacokinetic parameters were calculated by the 
least square linear regression technique described by GIBALDI and PERRIER (1982). The 
formulas used to compute various pharmacokinetic parameters were as follows. 
a) Half-life: distribution, elimination and absorption phases:
                 
0.693
i)  t1/2α  = 
                   
α
                 
0.693
ii) t1/2β    = 
                
     β
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 0.693
iii) t1/2k(a)   = 
                       
 k(a)
b) AUC(0 - t), the area under plasma drug concentration - time curve from time zero 
to time of last observed concentration  and AUMC, the area under the fi rst moment 
of the plasma drug concentration - time curve were calculated by the trapezoidal rule. 
Where as AUC(t - ∞) was calculated through dividing the last observed concentration 
by the elimination rate constant (β). AUC(0 - ∞) was calculated by the summation of 
AUC(0 - t) and AUC(t - ∞).
c) Vd(area), the apparent volume of distribution:
                         
Dose 
      Vd(area) =                                  (For intravenous injection)  
                    
β × (AUC)
                    
 Dose × F
      Vd(area) =                                  (For intramuscular injection)                                 
                    
β × (AUC)
d) Vd(ss), the volume of distribution of drug at steady state: 
                 
Dose × AUMC
Vd(ss)  =                                                     
                   
   (AUC)2
e) ClB, the total body clearance of drug:
 ClB  =  β × Vd(area) × 1000
f) MRT, the mean residence time:
                    
AUMC
     MRT   =   
                     
AUC
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g) F, the fraction of drug absorbed after non-vascular administration:
          
 Dose (i/v) ×  AUC (i/m)    
          
F =                                                              
           
Dose (i/m) ×  AUC (i/v)
Statistical analysis. The obtained results were presented as Mean ± SE The standard 
error of the mean was calculated according to SNEDECOR and COCHRAN (1976). 
Results
The semi-logarithmic plot of the plasma drug concentration as a function of time 
following the intravenous and intramuscular administration of ceftriaxone exhibited 
biexponential decline in the plasma drug concentration and could be best fi tted to a two-
compartment open model. The drug was detected in plasma up to 8 and 12 hours following 
intravenous and intramuscular administration, respectively. The comparative disposition 
of ceftriaxone following single dose intravenous and intramuscular administration in cow 
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Fig. 1. Semilogarithmic plot of ceftriaxone concentration in plasma versus time following single 
dose intravenous and intramuscular administration at the dose rate of 10 mg/kg of body mass in 
cow calves. Each point represents mean ± SE of six calves.
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Following intravenous administration of the drug, the elimination half-life (t1/2β), 
total body clearance (ClB), apparent volume of distribution (Vd(area)) and area under curve 
(AUC(0 - ∞)) were 1.58 ± 0.06
 h, 3.15 ± 0.41 mL/min/kg, 0.44 ± 0.07 L/kg and 57.35 
± 7.04 μg.h/mL, respectively. Following intramuscular administration, a peak plasma 
concentration of 15.34 ± 2.39 μg/mL was observed at 0.25 h. The values of elimination 
half-life (t1/2β), mean residence time (MRT) and area under curve (AUC (0 - ∞)) were 5.02 
± 0.51 h, 2.67 ± 0.13 h and 28.15 ± 2.02 μg.h/mL, respectively. The bioavailability of 
the drug following intramuscular injection was 47.0 ± 5.0%. Various pharmacokinetic 
parameters calculated from the plasma concentration of ceftriaxone after single dose 
intravenous and intramuscular administrations in cow calves are summarized in Table 1. 
Table 1. Pharmacokinetics of ceftriaxone after single dose intravenous and intramuscular 




(Mean ± SE) 
Intramuscular 
(Mean ± SE) 
Cp0 μg/mL 177.60 ± 6.16 -
t1/2 α h 0.13 ± 0.01 - 
t1/2β h 1.58 ± 0.06 5.02 ± 0.51 
AUC(0 - t) μg.h/mL 56.59 ± 6.34 26.69 ± 1.78
AUC(0 - ∞) μg.h/mL 57.35 ± 7.04 28.15 ± 2.02 
AUMC μg.h2/mL 61.65 ± 7.80 74.34 ± 3.86
Vd(area) L/kg 0.44 ± 0.07 1.16 ± 0.15
Vd(ss) L/kg 0.20 ± 0.03 -
Cl(B) mL/min/kg 3.15 ± 0.41 2.71 ± 0.29
MRT h 1.08 ± 0.03 2.67 ± 0.13 
F % - 47.0 ± 5.0
Cmax μg/mL - 15.34 ± 2.39
Tmax h - 0.25
Cpo: Theoretical concentration of drug in the plasma at zero time, t1/2α: half-life of distribution phases, t1/2β: 
elimination half-life, t1/2K(a): absorption half-life, AUC(0 - t): the area under plasma drug concentration - time curve 
from time zero to time of last observed concentration, AUC(0 - ∞): area under the plasma concentration-time 
curve from time zero to infinity, AUMC: area under fi rst of moment curve, Vd(area): volume of distribution of 
drug based on area, Vd(ss): volume of distribution of drug at steady-state, Cl(B): total body clearance, MRT: mean 
residence time, F: bioavailability, Cmax: maximum drug concentration; Tmax: time of maximum concentration 
observed in plasma 
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Discussion 
Following intravenous administration, a plasma ceftraiaxone concentration of 0.34 ± 
0.05 μg/mL was maintained for 8 hours above MIC (0.03 -0.2 μg/mL) of the drug against 
pathogenic bacteria of calves. JOHAL and SRIVASTAVA (1999) reported similar plasma 
levels in cross-bred calves; however SOBACK and ZIV (1988) reported a concentration 
of 0.1 μg/mL up to 10 hours following intravenous injection in neonatal calves. A peak 
plasma concentration of 15.34 ± 2.39 μg/mL was observed following intramuscular 
injection, which is lower than the concentrations of 20.3 ± 0.92, 23.6, and 23.16 ± 2.94 μg/
mL reported in cross-bred calves, goats and sheep, respectively (JOHAL and SRIVASTAVA, 
1998; ISMAIL, 2005, GOUDAH et al., 2006). A therapeutic ceftriaxone concentration (≥ 0.2 
μg/mL) was maintained in plasma for up to 12 hours following intramuscular injection in 
cow calves, which is longer than that observed in other studies (SOBACK and ZIV, 1988). 
Following intravenous administration of the drug, higher values of distribution rate 
constants and low values of elimination rate constants observed in the present study 
indicated that the drug was rapidly distributed and then relatively slowly eliminated in 
calves, which is in agreement with the high distribution rate constants (8.56 ± 1.69 h-1) and 
low elimination rate constants (0.30 ± 0.02 h-1) observed in buffalo calves (GAIKWAD, 
2001). The elimination half-life of the drug following intravenous administration in calves 
was 1.58 ± 0.06 h. This is in agreement with the half-life of ceftriaxone reported in sheep 
(1.7 and 1.75 ± 0.02 h) (GUERRINI et al., 1985; GOUDAH et al., 2006), calves (1.39 ± 
0.04 h) (SOBACK and ZIV, 1988), goats (1.44 h) (ISMAIL, 2005) and horses (1.62 ± 0.42 
h) (RINGGER et al., 1996). However, a longer elimination half-life of 4.39 ± 0.63 h has 
been reported in calves (JOHAL and SRIVASTAVA, 1999). The total body clearance of 
ceftriaxone in calves was 3.15 ± 0.41 mL/min/kg, which supports similar observations 
reported in sheep, calves, goats and mares (GUERRINI et al., 1985; SOBACK and ZIV, 1988; 
GARDENER and AUCOIN, 1994; ISMAIL, 2005; GOUDAH et al., 2006). However, faster 
clearance of the drug (5.16 ± 0.16 mL/min/kg) has been also observed in calves (JOHAL 
and SRIVASTAVA, 1998). The values of elimination half-life and total body clearance 
suggest faster elimination of cetriaxone following intravenous administration in cow 
calves. The apparent volume of distribution (0.44 ± 0.07 l/kg) of ceftriaxone in the present 
study was lower than the apparent volume of distribution of 1.19 ± 0.19 and 1.39 ± 0.08 
l/kg reported in cow and buffalo calves (JOHAL and SRIVASTAVA, 1998; GAIKWAD, 2001), 
respectively. 
Following the intramuscular administration of ceftriaxone in calves, the elimination 
half-life in the present study was 5.02 ± 0.51 h, which supports an elimination half-life 
of 6.54 ± 0.87 h reported in calves (JOHAL and SRIVASTAVA, 1998). However, a shorter 
elimination half-life of ceftriaxone has been reported in buffalo calves, dogs, goats and 
sheep (GAIKWAD, 2001; REBUELTO et al., 2002; ISMAIL, 2005; GOUDAH et al., 2006). 
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Following the intravenous and intramuscular administration of the drug, the variability 
in plasma drug concentration observed at 4 hours may be due to individual variation 
in elimination of the drug. The bioavailability of ceftriaxone following intramuscular 
administration was 47.0 ± 5.0%, which is close to the bioavailability of 40.0 ± 2.84% 
obtained in calves (JOHAL and SRIVASTAVA, 1998). However, higher bioavailability of 
ceftriaxone following intramuscular administration has been reported in cow calves, 
buffalo calves, goats and sheep (SOBACK and ZIV, 1988; GAIKWAD, 2001; ISMAIL, 
2005; GOUDAH et al., 2006). For Salmonella, Escherichia coli and Pasteurella multocida 
isolated from calves, ceftriaxone has MIC90 of 0.03 -0.2 μg/mL (SOBACK and ZIV, 1988). 
In spite of relative low intramuscular bioavailability, a therapeutically effective plasma 
concentration is attained at 5 minutes and maintained for 12 hours. The pharmacokinetic 
characteristics of ceftriaxone in cow calves following intravenous and intramuscular 
administration indicates this favorable pharmacokinetic profi le, hence the drug may be 
used to treat susceptible bacterial infections in cow calves.
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SAŽETAK
Farmakokinetika ceftriaksona određivana je u križane teladi nakon njegove jednokratne intravenske 
i intramuskularne primjene u dozi od 10 mg/kg. Koncentracija lijeka u plazmi određivana je tekućinskom 
kromatografi jom visokog učinka s UV zrakama. Raspodjela lijeka bila je brza nakon intravenske primjene (t1/2α: 
0,13 ± 0,01 h; Vd(area): 0,44 ± 0,07 L/kg), a izlučivanje (t1/2β: 1,58 ± 0,06 h) iz tijela s klirensom od 3,15 ± 0,41 
mL/min/kg. Nakon intramuskularne primjene vršna koncentracija u plazmi iznosila je (Cmax) 15,34 ± 2,39 μg/mL 
tijekom 0,25 sati (Tmax) što upućuje na vrlo brzu apsorpciju. Raspodjela lijeka bila je izrazito dobra (Vd(area) 1,16 
± 0,15 L/kg), a izlučivanje sporo (t1/2β: 5,02 ± 0,51 sati; Cl(B): 2,71 ± 0,29 mL/min/kg) nakon intramuskularne 
primjene. Apsolutna biološka raspoloživost nakon intramuskularne primjene ceftriaksona iznosila je 47,0 ± 
5,0%. Međutim, on se može rabiti u dozi od 10 mg/kg i.m. te ponavljati u razmacima od 12 sati radi liječenja 
bakterijskih zaraza u teladi.
Ključne riječi: farmakokinetika, biološka raspoloživost, ceftriakson, telad, intravenska primjena, 
intramuskularna primjena 
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